-
Pfizer receives prostate cancer drug boost with trial results
pharmafile
September 18, 2017
Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing it has received positive data for treating the condition at an early stage.
-
Exosome Diagnostics, CareFirst partner to speed up coverage for diagnostic tests
fiercebiotech
August 28, 2017
The partnership with Exosome Diagnostics is part of CareFirst's HealthWorx program, under which the insurance provider works with early-stage companies to accelerate health plan coverage of their products.
-
Recipharm and LIDDS establish industrial manufacturing capabilities for a novel prostate cancer prod
cphi-online
July 21, 2017
GMP Manufacturing line industrialised according to a unique process invented by LIDDS, involving the installation of novel equipment that is new to the pharmaceutical industry.
-
UMIT - Private University for Health Sciences Medical Informatics and Technology: Results of a Colla
en-cphi.cn
July 04, 2017
A simulation study published in BMC Public Health by researchers of the Tyrolean Health and Life Sciences University UMIT, the Oncotyrol center, the Medical University of Innsbruck and the University of Toronto highlights optimized use of prostate cancer
-
First prostate cancer patients treated with Augmenix's SpaceOAR Hydrogel in Israel
cphi-online
July 03, 2017
The Chaim Sheba Medical Center now offers the hydrogel spacer to reduce side-effects during prostate cancer radiation therapy.
-
Latest prostate cancer research could provide boost for J&J
June 06, 2017
Research funded by Cancer Research UK has found that abiraterone added to hormone therapy improved survival by over a third in those suffering from prostate cancer. The trial involved Johnson & Johnson’s Zytiga and could become a new standard of treatment
-
Early MRI may lower costs for prostate cancer treatment
europeanpharmaceuticalreview
May 26, 2017
A diagnostic MRI followed by one of three MRI-guided biopsy strategies is a cost-effective method to detect prostate cancer, according to a new study out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Cent
-
Dendreon eyes real-world data boost for lagging prostate cancer med Provenge
fiercepharma
May 16, 2017
Years after winning a hotly anticipated FDA approval for its cancer immunotherapy Provenge—and struggling to build sales of the prostate cancer med—Dendreon has racked up some real-world survival data it hopes can help.
-
Italian-style coffee reduces the risk of prostate cancer
worldpharmanews
April 28, 2017
Add another typical component of the Italian way of life to the long list of foods characterizing one of the most healthy populations in the world.
-
Is MRI the 'Mammography' of Prostate Cancer Screening?
drugs.com
March 27, 2017
MRI screening might greatly reduce overdiagnosis and overtreatment of prostate cancer in older men, a preliminary study suggests.